3-Ethoxy-6-(2-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)ethoxy)benzo[d]isoxazole bis(phosphate)

Catalog No. :
ACUKGF307
CAS No. :
1198151-75-5
Molecular Formula :
C21H32N4O11P2
Molecular Weight :
578.45

IUPAC Name:3-ethoxy-6-(2-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)ethoxy)benzo[d]isoxazole bis(phosphate)

3-Ethoxy-6-(2-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)ethoxy)benzo[d]isoxazole bis(phosphate) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
2mg98%$156.00Login to see priceInquiryInquiry
5mg98%$345.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-Ethoxy-6-(2-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)ethoxy)benzo[d]isoxazole bis(phosphate)
IUPAC Name3-ethoxy-6-(2-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)ethoxy)benzo[d]isoxazole bis(phosphate)
Molecular FormulaC21H32N4O11P2
Molecular Weight578.45
SMILESO=P(O)(O)O.CC1=NN=C(N2CCC(CCOC3=CC4=C(C=C3)C(OCC)=NO4)CC2)C=C1.O=P(O)(O)O
InChI KeyMIUFDXZDQWMWRR-UHFFFAOYSA-N
SynonymBTA798 diphosphate | 1,2-Benzisoxazole, 3-ethoxy-6-(2-(1-(6-methyl-3-pyridazinyl)-4-piperidinyl)ethoxy)-, phosphate (1:2) | HY-106254A | 3-Ethoxy-6-(2-(1-(6-methylpyridazin-3-yl)piperidin-4-yl)ethoxy)benzo[d]isoxazole bis(phosphate) | Vapendavir (diphosph
CAS No.1198151-75-5
PubChem CID44474071

Synthetic Route by SureRoute

1. ACUKGF307 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUKGF307 route product structure diagram
    ACUKGF3071198151-75-5
Inquiry

2. ACUKGF307 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACIRZD219 route compound structure diagram
    ACIRZD2191121-79-5 In Stock
  4. Then
  5. ACUKGF307 route product structure diagram
    ACUKGF3071198151-75-5
Inquiry

Comments (0)